Interval breast cancer is associated with other types of tumors

Graßmann, Felix; He, Weiling; Eriksson, Mikael; Gabrielson, Marike; Hall, Per; Czene, Kamila

doi:10.1038/s41467-019-12652-1

Cited by 32 publications

(36 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 , 4 , 5 When the relationship between method of breast cancer detection and outcome is provided, the effect size is rather small. 6 In this study, we used a population-based cancer registry to compare the biology and outcomes of SBC with those of IBC.…”

Section: Introductionmentioning

confidence: 99%

Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers

Niraula

Biswanger

et al. 2020

JAMA Netw Open

View full text Add to dashboard Cite

Key Points Question What are the differences and similarities in characteristics and outcomes of breast cancers detected by mammographic screening vs those detected between screening mammograms (interval cancers) in women participating in a population-based screening program? Findings In this cohort study of 69 025 women, interval breast cancers accounted for one-fourth of breast cancers in routinely screened women, were 6 times more likely to be grade III, and had 3.5 times increased hazards of breast cancer death compared with screen-detected cancers. Meaning Heterogeneity in breast cancer defies assumptions necessary for screening mammography in its current form to be maximally effective; strategies beyond routine screening mammography are needed to prevent, detect, and avert deaths from the more lethal interval breast cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers

Niraula

Biswanger

et al. 2020

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…This may partly explain our findings on the particularly worse prognosis of BCa-2 after ovarian cancer. A recent study also showed that breast cancer developed between two screenings, a known type of worse prognosis, is more likely to have a non-breast malignancy before and after breast cancer diagnosis, potentially through rare deleterious mutations in cancer genes [ 12 ]. Further research is warranted to understand mutations leading to BCa-2 after other malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…This is partly attributable to intensive cancer treatment for the first malignancy (e.g., radiotherapy [8] and chemotherapy [1]), as well as certain lifestyle (e.g. smoking [9,10]) and genetic factors [11,12] that predisposed the individual to both first and second malignancies. Compared with the general population, high-dose chest radiation or exposure to alkylator or anthracycline was associated with drastically increased risk of subsequent breast cancer among childhood cancer survivors [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy

Wang

Deng

et al. 2021

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Cancer survivors who develop breast cancer as a second malignancy (BCa-2) are common. Yet, little is known about the prognosis of BCa-2 compared to first primary breast cancer (BCa-1). Methods Using the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 883,881 patients with BCa-1 and 36,313 patients with BCa-2 during 1990–2015. Compared with patients with BCa-1, we calculated hazard ratios (HRs) of breast cancer-specific mortality among patients with BCa-2, using multivariable Cox regression. Results During the follow-up (median 5.5 years), 114,964 and 3829 breast cancer-specific deaths were identified among BCa-1 and BCa-2 patients, respectively. Patients with BCa-2 had more favorable tumor characteristics and received less intensive treatment e.g., surgery and chemo−/radio-therapy, compared to patients with BCa-1. When adjusting for demographic factors, patients with BCa-2 were at similar risk of breast cancer-specific mortality (HR 1.00, 95% CI 0.97–1.03) compared to patients with BCa-1. However, when additionally controlling for tumor characteristics and treatment modes, BCa-2 patients were at an increased risk of breast cancer-specific mortality (HR 1.11, 95% CI 1.08–1.15). The risk elevation was particularly greater when the first malignancy was lung, bladder, ovarian or blood malignancy (HRs 1.16–1.85), or when the first malignancy was treated with chemotherapy and radiotherapy (HR 1.44, 95% CI 1.28–1.63). Conclusions Overall, patients with BCa-2 have worse breast cancer-specific survival, compared with their BCa-1 counterparts, although the risk elevation is mild. High-risk subgroups based on first malignancy’s characteristics may be considered for active clinical management.

show abstract

“…Mammography X‐ray image is able to detect 70%–80% of breast cancers; the remnants (20%–30%) are detected between screen intervals, and unfortunately are of the more aggressive type, namely triple negative. [ 271 ] For PDAC, symptoms are not specific, which causing advanced metastatic stage upon diagnosis. [ 54 ] Survival from cancer can impose other health issues in aged populations.…”

Section: Challenges In Regard To Tumors Of Solid Organs and Therapymentioning

confidence: 99%

The current knowledge concerning solid cancer and therapy

Najafi

Majidpoor

Toolee

et al. 2021

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are a number of strategies for addressing tumors raised from solid organs including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, combinational therapy, and stem cell and extracellular vesicle (EV) therapy. Surgery, radiotherapy, and chemotherapy are the dominant cures, but are not always effective, in which even in a localized tumor there is a possibility of tumor relapse after surgical resection. Over half of the cancer patients will receive radiotherapy as a part of their therapeutic schedule. Radiotherapy can cause an abscopal response for boosting the activity of the immune system outside the local field of radiation, but it may also cause an unwanted bystander effect, predisposing nonradiated cells into carcinogenesis. In the context of immunotherapy, immune checkpoint inhibition is known as the standard‐of‐care, but the major concern is in regard with cold cancers that show low responses to such therapy. Stem‐cell therapy can be used to send prodrugs toward the tumor area; this strategy, however, has its own predicaments, such as unwanted attraction toward the other sites including healthy tissues and its instability. A substitute to such therapy and quite a novel strategy is to use EVs, by virtue of their stability and potential to cross biological barriers and long‐term storage of contents. Combination therapy is the current focus. Despite advances in the field, there are still unmet concerns in the area of effective cancer therapy, raising challenges and opportunities for future investigations.

show abstract

Interval breast cancer is associated with other types of tumors

Cited by 32 publications

References 58 publications

Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers

Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers

Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy

The current knowledge concerning solid cancer and therapy

Contact Info

Product

Resources

About